Rajsekar Rajaraman
Neurology with Special Qualifications in Child Neurology · Los Angeles, CANPI 1104144690
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $87,250 of the $133,834 with a category attached, or 65.2%. 25 manufacturers reported payments, led by Immedica Pharma US, Inc. at 36.4% of the total. 2025 is the largest year on record at $52,805, more than ten times the $1,797 reported in 2019. Among neurology with special qualifications in child neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 246 payments — averaging $544.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Immedica Pharma US, Inc.$49K
- Acadia Pharmaceuticals Inc$43K
- Jazz Pharmaceuticals Inc.$17K
- UCB, Inc.$10K
- UCB SA$6K
- Lundbeck LLC$3K
- plus $5K from 19 others
Across 146 payments — averaging $9252.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$372K
- Ultragenyx Pharmaceutical Inc.$315K
- Immedica Pharma US, Inc.$281K
- Takeda Pharmaceuticals U.S.A., Inc.$134K
- UCB SA$133K
- H. Lundbeck A S$61K
- plus $55K from 2 others
What the payments were for
- Consulting fees$26,93020%
- Speaking & faculty fees$87,25065%
- Travel & lodging$11,9889%
- Food & beverage$7,6676%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Immedica Pharma US, Inc. | 64 | $48,776 |
| Acadia Pharmaceuticals Inc | 53 | $43,326 |
| Jazz Pharmaceuticals Inc. | 37 | $17,100 |
| UCB, Inc. | 41 | $10,018 |
| UCB SA | 4 | $5,845 |
| Lundbeck LLC | 3 | $3,434 |
| UCB Biosciences Inc. | 1 | $1,800 |
| Supernus Pharmaceuticals, Inc. | 2 | $628 |
| Greenwich Biosciences, Inc. | 5 | $522 |
| Vertex | 1 | $400 |
| SK Life Science, Inc. | 3 | $271 |
| Biocodex, Inc. | 4 | $270 |
| H. Lundbeck A S | 1 | $241 |
| Sunovion Pharmaceuticals Inc. | 2 | $176 |
| Medtronic | 1 | $172 |
| Neurelis, Inc. | 5 | $164 |
| Eisai Inc. | 1 | $125 |
| Nobelpharma America, LLC | 5 | $124 |
| Upsher-smith Laboratories LLC | 4 | $95 |
| Neuropace, Inc. | 2 | $94 |
| Zogenix Inc. | 1 | $93 |
| Pyros Pharmaceuticals, Inc. | 2 | $62 |
| Livanova USA, Inc. | 2 | $39 |
| Catalyst Pharmaceuticals, Inc. | 1 | $29 |
| Biomarin Pharmaceutical Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$133,834 in reported general payments places this provider in the 95th percentile of 216 neurology with special qualifications in child neurology providers in California.
See all neurology with special qualifications in child neurology providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HyftorSirolimus | 11 | $67,658 |
| LamictalLamotrigine | 25 | $39,119 |
| TopamaxTopiramate | 12 | $37,963 |
| XcopriCenobamate | 26 | $28,769 |
| FycompaPerampanel | 12 | $16,710 |
| Clobazam | 59 | $12,964 |
| Rufinamide | 12 | $10,453 |
| Lacosamide | 31 | $5,580 |
| Levetiracetam | 25 | $632 |
| Zonisamide | 11 | $320 |
| Topiramate | 12 | $108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Nobelpharma America, LLCHyftor | $124 | $67,65811 claims |
| SK Life Science, Inc.Xcopri | $271 | $28,76926 claims |
| Eisai Inc.Fycompa | $125 | $16,71012 claims |
| Upsher-smith Laboratories LLCTopiramate | $95 | $10812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 216 neurology with special qualifications in child neurology providers in California.
Other neurology with special qualifications in child neurology in Los Angeles
- Deborah HolderLos Angeles$130K
- Leigh Maria Ramos PlattLos Angeles$59K
- Shaun HussainLos Angeles$40K
- Mohsen HamzaLos Angeles$24K
- Tena RosserLos Angeles$7K
- Arthur PartikianLos Angeles$7K
- Michael ChezSacramento$374K
- Allen BottOakland$372K
- Joseph SullivanSan Francisco$240K
- Ann SegerenStanford$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.